BofA raised the firm’s price target on Novartis to CHF 115 from CHF 106 and keeps a Buy rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVS:
- Novartis issues voluntary recall of one lot of Sandimmune Oral Solution
- Novartis issues voluntary recall of one lot of Sandimmune oral solution
- Sandoz announces exclusive deal to commercialize biosimilar ustekinumab
- Novartis upgraded to Buy from Hold at Erste Group
- Novartis names AbbVie’s Patrick Horber as President, International